Mp10-06 Elevated Eosinophils Before 2 Course Treatment May Be a Universal Biomarker for Immune-Related Adverse Events Induced by Common to Different Immune Checkpoint Inhibitor and Cancer Types Including to Urological Cancer

You have accessJournal of UrologyKidney Cancer: Advanced (including Drug Therapy) I (MP10)1 May 2024MP10-06 ELEVATED EOSINOPHILS BEFORE 2 COURSE TREATMENT MAY BE A UNIVERSAL BIOMARKER FOR IMMUNE-RELATED ADVERSE EVENTS INDUCED BY COMMON TO DIFFERENT IMMUNE CHECKPOINT INHIBITOR AND CANCER TYPES INCLUDING TO UROLOGICAL CANCER Yoshihiko Tasaki, Shuzo Hamamoto, Taku Naiki, Toshiki Etani, Shoichiro Iwatsuki, Rei Unno, Takashi Nagai, Yoshihisa Mimura, Yosuke Sugiyama, Yuji Hotta, Atsushi Okada, Takahiro Yasui, and Yoko Furukawa-Hibi Yoshihiko TasakiYoshihiko Tasaki , Shuzo HamamotoShuzo Hamamoto , Taku NaikiTaku Naiki , Toshiki EtaniToshiki Etani , Shoichiro IwatsukiShoichiro Iwatsuki , Rei UnnoRei Unno , Takashi NagaiTakashi Nagai , Yoshihisa MimuraYoshihisa Mimura , Yosuke SugiyamaYosuke Sugiyama , Yuji HottaYuji Hotta , Atsushi OkadaAtsushi Okada , Takahiro YasuiTakahiro Yasui , and Yoko Furukawa-HibiYoko Furukawa-Hibi View All Author Informationhttps://doi.org/10.1097/01.JU.0001008588.39303.c9.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Immune checkpoint inhibitors (ICIs) cause severe immune-related adverse events (irAEs). Our previous study showed increased eosinophil of ≥3.0% is a biomarker for predicting irAEs in renal cell carcinoma received anti-CTLA-4 plus anti-PD-1 therapy. However, its universal biomarker in different ICIs and cancers has not been identified. This study examined whether eosinophils can be a universal biomarker for irAEs. METHODS: 614 patients with various cancers (renal cell, urothelial, esophageal, gastric, head and neck, lung, melanoma, and other cancer) received with anti-PD-1, anti-PD-L1, or anti-CTLA-4 plus anti-PD-1 therapy. We divided into two groups depending on whether patients had experienced an irAEs (irAE group) or not (non-irAE group). Eosinophils were examined before 2-course of treatment. RESULTS: The irAE group of renal cell carcinoma received anti-PD-1 or anti-CTLA-4 plus anti-PD-1 therapy had higher eosinophils than the non-irAE group (Figure 1; p<0.05). Furthermore, eosinophils in urothelial, gastric, head and neck, lung cancers, and melanoma received anti-PD-1, anti-PD-L1, or anti-CTLA-4 plus anti-PD-1 therapy were higher in the irAE group than in the non-irAE group (Figure 1; p<0.05). In multivariate analyses, eosinophils of ≥3.0% were an independent factor for irAEs (odds ratio 2.57, 95% CI 1.79–3.67). CONCLUSIONS: An increased eosinophil before the 2-course treatment may be a universal biomarker for irAEs common to different ICIs and cancers, not just renal cell carcinoma received anti-CTLA-4 plus anti-PD-1 therapy (Figure 2). Download PPTDownload PPT Source of Funding: The Nitto Foundation © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e139 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Yoshihiko Tasaki More articles by this author Shuzo Hamamoto More articles by this author Taku Naiki More articles by this author Toshiki Etani More articles by this author Shoichiro Iwatsuki More articles by this author Rei Unno More articles by this author Takashi Nagai More articles by this author Yoshihisa Mimura More articles by this author Yosuke Sugiyama More articles by this author Yuji Hotta More articles by this author Atsushi Okada More articles by this author Takahiro Yasui More articles by this author Yoko Furukawa-Hibi More articles by this author Expand All Advertisement PDF downloadLoading ...